TransMedics Group, Inc. announced the launch of its Controlled Hypothermic Organ Preservation System (CHOPS) during the International Society of Heart and Lung Transplantation (ISHLT) 2026 Annual Meeting in Toronto. The new device, unveiled on April 23 2026, provides a stable, active‑cooling environment for donor organs and will serve as the control arm for the company’s OCS ENHANCE Heart Part B and OCS DENOVO Lung clinical trials.
The launch follows the FDA’s full Investigational Device Exemption approvals for the two trials—February 2026 for OCS ENHANCE Heart and January 2026 for OCS DENOVO Lung. CEO Waleed Hassanein said, "Now that we have full and unconditional IDE approvals for both OCS ENHANCE Heart and DENOVO Lung trials, we are focused on trial execution and patient enrollment." The company expects the outcomes of these trials to act as major catalysts for heart and lung adoption in 2026 and beyond.
By adding an active‑cooling system, CHOPS expands TransMedics’ portfolio beyond its existing warm‑perfusion OCS platform. The device broadens the company’s market reach to centers that prefer or require hypothermic preservation, positioning TransMedics as a comprehensive organ‑preservation solution provider. The launch is a material development that may influence future product mix and the results of the ongoing trials.
The organ‑preservation market is competitive, with other players such as OrganOx Limited also developing innovative solutions. Industry trends show a growing demand for technologies that extend organ viability and improve transplant outcomes. CHOPS’ introduction strengthens TransMedics’ competitive stance and supports its strategy to support next‑generation clinical programs.
The announcement is a material event that could reshape TransMedics’ product strategy and the trajectory of its heart and lung trials. Investors should view the launch as a key milestone that may affect the company’s future revenue mix and clinical success rates.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.